Seoul – October 12, 2026 -- Lunit (KRX: 328130) has partnered with Discovery Life Sciences, a lab that supports more than 350 active clinical trial programs, to roll out the Lunit SCOPE suite across biopharmaceutical research.

The AI-powered pathology platform will run inside Discovery's biomarker and tissue analysis workflows. Both companies will tailor it to each client program's design, working directly with pharmaceutical and biotechnology customers.

Rockville, Md. – October 12, 2026 -- REGENXBIO Inc. (Nasdaq: RGNX) will host a three-hour investor event on October 20, 2026 to review its wet age-related macular degeneration (wet AMD) gene therapy program, with topline pivotal data anticipated in the fourth quarter of 2026.

Event runs 1:00 p.m. to 4:00 p.m. ET in New York and online

The session will be held in person in New York and streamed by webcast. It will cover the clinical program for surabgene lomparvovec (sura-vec, ABBV-RGX-314), which REGENXBIO is developing in collaboration with AbbVie.

Laval – October 12, 2026 -- A six-month pilot of a standardized cirrhosis clinical pathway raised follow-up office visit adherence by 9.0% in relative terms, to 51.1% from 46.9%, across 4,251 patients in five community gastroenterology practices, Bausch Health Companies Inc. and its GI unit Salix Pharmaceuticals announced.

Guangzhou – October 12, 2026 -- Nasdaq-listed Pomdoctor Limited (POM) said it will integrate AI, wearable devices, remote patient monitoring (RPM) and real-world healthcare data with its existing physician resources, aiming to move care from "diagnose and treat" to "predict, alert and intervene."

Seoul – October 12, 2026 -- Parkinson's patients taking the investigational drug solengepras gained an average of 36 more minutes of "good" movement time per day than those on their regular medication alone, and the drug will now be submitted to the U.S. Food and Drug Administration for approval.

Beijing – October 12, 2026 -- T-MAXIMUM PHARMACEUTICAL has received FDA clearance to start a Phase 2 study of MT027, its B7-H3-targeted allogeneic CAR-T therapy, in patients with brain metastases from lung and breast cancer. It is the second Phase 2 program for the asset to clear the agency.

Seoul – October 12, 2026 -- CLASSYS Inc. (KOSDAQ: 214150) has created the post of Chief Commercial Officer and appointed former Bain & Company partner Jung-hee Bae to it, tasking her with a push toward a $1 billion revenue target ahead of 2030. Bae, who also becomes Vice President, will head the company's newly formed Go-to-Market (GTM) Center.

Linköping – October 12, 2026 -- UK digital pathology provider Diagnexia has signed an annual, renewable agreement with Sectra (STO: SECT B) covering up to 100,000 cases in the first year, enabling it to receive, send and report pathology cases digitally for NHS organisations.

The contract was signed in the second quarter of Sectra's 2026/2027 fiscal year. It uses Sectra's service for advanced share and collaborate workflows to connect Diagnexia with NHS bodies that need external specialist support.

Kuala Lumpur – October 12, 2026 -- ASEAN Records has recognised Malaysia's ECO Bee Biotech Sdn Bhd for the first alcohol-free Halal Kelulut Golden Propolis extract made with Supercritical Fluid Extraction (SFE), a product developed with three Malaysian universities and honoured on innovation platforms in Malaysia, Canada and Croatia.

San Carlos – October 12, 2026 -- Fierce MedTech has named Noah Medical one of its 2023 "Fierce 15" medical technology companies, citing the growth of the Galaxy System, the company's first commercial platform for robotic navigated bronchoscopy.

Fierce MedTech credited Noah Medical's long-term plan to improve early diagnosis and treatment across multiple indications. The Galaxy System is a fully image-integrated platform aimed at minimally invasive early lung cancer diagnosis.